SS-20

SS-20 is a synthetic peptide, also called SBT-20 or SBT-020, studied for mitochondrial function. People discuss energy, longevity and SS-31 comparisons, but direct SS-20 experience remains sparse.

A synthetic mitochondrial peptide. Its four-amino-acid sequence is Phe-D-Arg-Phe-Lys-NH2. Mitochondria produce energy inside cells. van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease (Official context · Accessed 2026-09-30)

Related to SS-31, with different chemistry. SS-20 lacks SS-31’s dimethyltyrosine, an amino acid responsible for direct radical scavenging. Animal work nevertheless finds cardiolipin binding: interaction with a membrane fat that helps organize energy production. That distinction explains why it can help some stressed mitochondria without behaving like SS-31 in every experiment. Birk et al. — Disruption of cytochrome c heme coordination during ischemia (Animal context · Accessed 2026-09-30)

Different from mitochondrial-derived peptides. MOTS-c and humanin belong to another peptide group. Their shared mitochondrial topic does not make them forms of SS-20.

Energy and longevity are the hoped-for benefits. Community descriptions connect healthier mitochondria with steadier energy, recovery and aging. The original discussion record treats SS-20 as a lesser-known sibling, not a stimulant or a compound with a dependable healthy-user response pattern. Those goals are reasons for interest, not established outcomes.

Forum enthusiasm is mainly about the SS family. Science for ME members share mitochondrial literature; the SS-20 passages describe an analog without direct scavenging, not a fatigue recovery diary. LongeCity members ask how SS peptides compare with MitoQ while quoting experiments where SS-20 failed to protect an isolated heart. Those are laboratory comparisons, not users reporting treatment success or failure. Science for ME — Treatment of mitochondria with antioxidants SS-19 and SS-31 (Community discussion · Accessed 2026-09-30) · LongeCity — Mitochondria-targeted peptide SS-31 (Community discussion · Accessed 2026-09-30)

Source context — van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease: Small, short, monitored disease-population trial, not wellness experience. Healthy-volunteer dose list is background, not separately inspected trial data. Discussion labels an additional multi-dose PK range Part 2 Day 7 although Part 2 sampling is described as trough-only; no correction or combined range inferred. The dose rationale also gives 0.76 mg/kg and 4.5 mg for 60 kg, which do not reconcile arithmetically; the intended correction is unknown. Main PMC browser URL was CAPTCHA-blocked, alternate public Europe PMC XML succeeded.

Source context — Birk et al. — Disruption of cytochrome c heme coordination during ischemia: Animal/isolated mitochondria and membrane assays; no personal energy, consumer dose, tissue half-life or duration inferred. Authors/Cornell disclose financial interests in licensed SS peptides.

Source context — Science for ME — Treatment of mitochondria with antioxidants SS-19 and SS-31: Patient-community literature discussion, not firsthand administration. Quoted review results stay laboratory-origin claims. Embedded tweet was not inspected on X and is not used as an SS-20 report.

Source context — LongeCity — Mitochondria-targeted peptide SS-31: SS-31-focused thread with research quotations and opinions. No SS-20 dose diary or measured personal response. Cell-safety speculation is not accepted as human safety. First open timed out; a second open returned the actual body.

Energy and longevity are the hoped-for benefits. Community descriptions connect healthier mitochondria with steadier energy, recovery and aging. The original discussion record treats SS-20 as a lesser-known sibling, not a stimulant or a compound with a dependable healthy-user response pattern. Those goals are reasons for interest, not established outcomes.

Forum enthusiasm is mainly about the SS family. Science for ME members share mitochondrial literature; the SS-20 passages describe an analog without direct scavenging, not a fatigue recovery diary. LongeCity members ask how SS peptides compare with MitoQ while quoting experiments where SS-20 failed to protect an isolated heart. Those are laboratory comparisons, not users reporting treatment success or failure. Science for ME — Treatment of mitochondria with antioxidants SS-19 and SS-31 (Community discussion · Accessed 2026-09-30) · LongeCity — Mitochondria-targeted peptide SS-31 (Community discussion · Accessed 2026-09-30)

No overall benefit on the study’s function measures. Mitochondrial, motor and cognitive outcomes showed no overall benefit versus placebo. Subgroup signals remained exploratory. van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease (Official context · Accessed 2026-09-30)

Investigational amounts, separately from community claims. Active early-Huntington’s study arms used 5, 15 or 25 mg SubQ daily for seven days; after ≥1 month’s washout, 25 mg daily for 28 days. Earlier healthy-volunteer assessments used 5, 10, 20 and 30 mg. van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease (Official context · Accessed 2026-09-30)

Source context — Science for ME — Treatment of mitochondria with antioxidants SS-19 and SS-31: Patient-community literature discussion, not firsthand administration. Quoted review results stay laboratory-origin claims. Embedded tweet was not inspected on X and is not used as an SS-20 report.

Source context — LongeCity — Mitochondria-targeted peptide SS-31: SS-31-focused thread with research quotations and opinions. No SS-20 dose diary or measured personal response. Cell-safety speculation is not accepted as human safety. First open timed out; a second open returned the actual body.

Source context — van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease: Small, short, monitored disease-population trial, not wellness experience. Healthy-volunteer dose list is background, not separately inspected trial data. Discussion labels an additional multi-dose PK range Part 2 Day 7 although Part 2 sampling is described as trough-only; no correction or combined range inferred. The dose rationale also gives 0.76 mg/kg and 4.5 mg for 60 kg, which do not reconcile arithmetically; the intended correction is unknown. Main PMC browser URL was CAPTCHA-blocked, alternate public Europe PMC XML succeeded.

1–5 mg per administration is a chart claim. PeptideWiki lists daily subcutaneous use, meaning under the skin. It supplies no matching dosing study or personal log. This is an online reference claim, not an established SS-20 community band. PeptideWiki — SS-20 calculator and reference (Community guide · Accessed 2026-09-30)

SS-31 amounts do not transfer to SS-20. The original record preserves borrowed injectable bands of 2–5 mg, 5–10 mg and 10–20+ mg, without a dependable SS-20 course behind them. A promotional Reddit chart actually labels its 5–10 mg daily SubQ row SS-31. Neither provides SS-20-specific dosing evidence. JustBacWater — The Only Peptide Cheat Sheet You'll Need (Community guide · Accessed 2026-09-30)

Investigational amounts, separately from community claims. Active early-Huntington’s study arms used 5, 15 or 25 mg SubQ daily for seven days; after ≥1 month’s washout, 25 mg daily for 28 days. Earlier healthy-volunteer assessments used 5, 10, 20 and 30 mg. van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease (Official context · Accessed 2026-09-30)

Source context — PeptideWiki — SS-20 calculator and reference: Creator/reference chart, not personal experience. No named study supports 1–5 mg per administration or two-hour half-life. The page incorrectly excludes published human SBT-020 research. Arithmetic modeling and calculator recipes are not retained.

Source context — JustBacWater — The Only Peptide Cheat Sheet You'll Need: Commercial influence is explicit through vendor links and discount code. This row is SS-31, not SS-20; included solely to identify borrowed numbers, not to supply an SS-20 protocol. Publicly available post/replies, not all collapsed replies.

Source context — van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease: Small, short, monitored disease-population trial, not wellness experience. Healthy-volunteer dose list is background, not separately inspected trial data. Discussion labels an additional multi-dose PK range Part 2 Day 7 although Part 2 sampling is described as trough-only; no correction or combined range inferred. The dose rationale also gives 0.76 mg/kg and 4.5 mg for 60 kg, which do not reconcile arithmetically; the intended correction is unknown. Main PMC browser URL was CAPTCHA-blocked, alternate public Europe PMC XML succeeded.

No reproducible SS-20 benefit onset was found. The original notes describe SS-31 expectations of steadier energy in weeks two to four being borrowed for SS-20. They are not SS-20 diaries. The opened forums also discuss literature rather than a firsthand course, so there is no sound hours-to-days promise here. Science for ME — Treatment of mitochondria with antioxidants SS-19 and SS-31 (Community discussion · Accessed 2026-09-30) · LongeCity — Mitochondria-targeted peptide SS-31 (Community discussion · Accessed 2026-09-30)

Felt duration and benefit after stopping are unknown. There is no identifiable SS-20 account here that follows a systemic benefit through a dose, a day and a break. Older notes also flag scarce months-long experience. Neither a daily schedule nor a mitochondrial mechanism establishes how long someone would feel better.

Investigational amounts, separately from community claims. Active early-Huntington’s study arms used 5, 15 or 25 mg SubQ daily for seven days; after ≥1 month’s washout, 25 mg daily for 28 days. Earlier healthy-volunteer assessments used 5, 10, 20 and 30 mg. van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease (Official context · Accessed 2026-09-30)

Measured plasma timing, not a felt-effect clock. Day-seven half-lives were 3.13, 3.94 and 4.14 hours, respectively. Other reported summaries: 3.47–3.74 hours single-dose; 3.51–5.26 hours multiple-dose, inconsistently phase-labeled. These are not averaged. Blood peaks: 0.5–1 hour. Weekly sampling found no accumulation across 28 days. van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease (Official context · Accessed 2026-09-30)

Two hours is an assumption in an online reference. PeptideWiki attributes its value to similarity with related peptides, not human SS-20 measurements. Plasma half-life describes falling blood concentration; it cannot time a benefit or justify repeat dosing. PeptideWiki — SS-20 calculator and reference (Community guide · Accessed 2026-09-30)

Source context — Science for ME — Treatment of mitochondria with antioxidants SS-19 and SS-31: Patient-community literature discussion, not firsthand administration. Quoted review results stay laboratory-origin claims. Embedded tweet was not inspected on X and is not used as an SS-20 report.

Source context — LongeCity — Mitochondria-targeted peptide SS-31: SS-31-focused thread with research quotations and opinions. No SS-20 dose diary or measured personal response. Cell-safety speculation is not accepted as human safety. First open timed out; a second open returned the actual body.

Source context — van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease: Small, short, monitored disease-population trial, not wellness experience. Healthy-volunteer dose list is background, not separately inspected trial data. Discussion labels an additional multi-dose PK range Part 2 Day 7 although Part 2 sampling is described as trough-only; no correction or combined range inferred. The dose rationale also gives 0.76 mg/kg and 4.5 mg for 60 kg, which do not reconcile arithmetically; the intended correction is unknown. Main PMC browser URL was CAPTCHA-blocked, alternate public Europe PMC XML succeeded.

Source context — PeptideWiki — SS-20 calculator and reference: Creator/reference chart, not personal experience. No named study supports 1–5 mg per administration or two-hour half-life. The page incorrectly excludes published human SBT-020 research. Arithmetic modeling and calculator recipes are not retained.

No SS-20 on/off consensus is established. The original record includes borrowed four-to-eight-week evaluation windows and three-months-on, one-month-off language, explicitly traced to SS-31 comparisons. The Reddit guide’s four-to-eight-week course and two-to-four-week break likewise belong to SS-31. Cost, daily needles and local irritation are preserved reasons people discuss pausing, not a validated SS-20 calendar. JustBacWater — The Only Peptide Cheat Sheet You'll Need (Community guide · Accessed 2026-09-30)

Source context — JustBacWater — The Only Peptide Cheat Sheet You'll Need: Commercial influence is explicit through vendor links and discount code. This row is SS-31, not SS-20; included solely to identify borrowed numbers, not to supply an SS-20 protocol. Publicly available post/replies, not all collapsed replies.

Stack talk is adjacency rather than demonstrated synergy. The preserved discussion places SS-20 alongside MOTS-c, humanin, NAD precursors, CoQ10, PQQ, urolithin A and methylene blue. The familiar SS-31-before-MOTS-c story is not evidence for SS-20 sequencing. Sleep and training changes complicate subjective comparisons; silence is not a reason to assume the dose was too low.

Vs SS-31 (primary comparison, not a stack): Discussed as the non-Dmt sibling / historical control peptide. Dual SS-20 + SS-31 stacks are low-volume and poorly documented; most serious talk is which analog, not both. [community]

Local reactions occurred in the human study. Redness, swelling, pain and itching were mild, generally starting within minutes and resolving within an hour. Consumer-product safety remains unknown. van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease (Official context · Accessed 2026-09-30)

Identity and missing safety information matter. Community cautions include substitution with SS-31, uncertain contents and little long-term healthy-user information. Older mitochondrial discussions raise theoretical cancer concerns; these are not demonstrated SS-20 cancer effects. Pregnancy, medication interactions and complex mitochondrial illness cannot be resolved through generic peptide charts.

Source context — van Diemen et al. — Safety, pharmacokinetics and pharmacodynamics of SBT-020 in early Huntington’s disease: Small, short, monitored disease-population trial, not wellness experience. Healthy-volunteer dose list is background, not separately inspected trial data. Discussion labels an additional multi-dose PK range Part 2 Day 7 although Part 2 sampling is described as trough-only; no correction or combined range inferred. The dose rationale also gives 0.76 mg/kg and 4.5 mg for 60 kg, which do not reconcile arithmetically; the intended correction is unknown. Main PMC browser URL was CAPTCHA-blocked, alternate public Europe PMC XML succeeded.